Related Experiment Video

Updated: Sep 29, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Fluoroquinolones for the treatment of outpatient community-acquired pneumonia

Ronald N Jones1, Lionel A Mandell

  • 1The JONES Group/JMI Laboratories, North Liberty, Iowa, USA. ronald-jones@jmilabs.com

Diagnostic Microbiology and Infectious Disease
|October 12, 2002
PubMed

Insights

Fluoroquinolones are crucial for treating respiratory infections due to rising antibiotic resistance. Understanding their varying safety profiles and local resistance is key for effective patient treatment.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Increasing resistance to beta-lactam and macrolide antibiotics necessitates novel antimicrobial strategies.
  • Fluoroquinolones offer broad-spectrum activity, good oral absorption, and convenient dosing, making them vital in treating respiratory infections.
  • This class of antibiotics is widely used in both community and hospital environments.

Purpose of the Study:

  • To provide an overview of fluoroquinolone antibiotics.
  • To highlight the importance of considering in vitro activity, susceptibility patterns, adverse effects, and drug interactions when selecting fluoroquinolones.
  • To focus on the application of fluoroquinolones in community-acquired pneumonia and their safety profiles.

Main Methods:

  • Literature review of fluoroquinolone properties and clinical applications.
  • Analysis of antimicrobial resistance trends.
  • Evaluation of safety profiles and drug interactions.

Main Results:

  • Fluoroquinolones are a significant therapeutic option for respiratory infections, especially with rising resistance to other agents.
  • Individual fluoroquinolone agents possess distinct safety profiles and potential drug interactions.
  • Effective use requires knowledge of local resistance patterns and patient-specific factors.

Conclusions:

  • Fluoroquinolone selection for respiratory infections should be guided by microbial susceptibility, safety data, and drug interactions.
  • Optimizing fluoroquinolone therapy is essential for managing community-acquired pneumonia and ensuring patient safety.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...